ABT vs ADBE Stock Comparison

Scores Breakdown

Metric	ABT	ADBE
📈 Growth	18/30	22/30
💰 Profitability	17/20	17/20
🏦 Financial Health	18/20	16/20
💵 Valuation	12/20	12/20
⚠️ Risk (lower is better)	4/10	4/10
Overall Score	71/100	73/100

Side-by-Side Summaries

ABT Analysis	ADBE Analysis
📈 Growth & Financial Trajectory Across the observed quarters from 2024-Q2 through 2026-Q2 Abbott Laboratories shows an 8-quarter style revenue uptick, with Revenues rising from about $10.635B to $12.593B (+~~18%). Net income fluctuates, starting around $1.306B and ending near $0.928B, signaling earnings volatility despite top-line strength. Operating income remains solid (~~$1.69B in 2026-Q2) and gross margins stay in the high-50s, roughly a Gross Margin of 57–58%. Cash generation is resilient: quarterly operating cash flow from continuing activities was strong (e.g., around $2.49B in 2026-Q2), but total net cash flow swung negative in some periods due to financing activity, yielding a negative net cash flow of about $1.70B. 💰 Margins & Cash Flow Gross Margin: high-50s to ~58%; Operating Margin around 13–14% in the latest quarter. Operating cash flow from continuing activities generally robust; Net cash flow can be negative when financing activity dominates, as seen in 2026-Q2 (-$1.70B). 🛡️ Balance Sheet & Liquidity Total assets approx $109B with Equity around $51.8B and Liabilities near $57.5B. Current assets vs current liabilities yields a Current ratio near 1.38, indicating solid liquidity. Leverage is moderate given the equity base and stable cash flow. ⚠️ Key Drivers & Risks Drivers: Diversified product portfolio supporting recurring revenues; demand for diagnostics and chronic-care management. Risks: Earnings volatility across quarters; cash flow sensitivity to financing activities and potential regulatory/currency shifts.	📈 Growth & Financial Trajectory Over 8 quarters, revenue rose from $5.714B (Q2 2024) to $6.618B (Q2 2026), up about 16%. Net income grew from $1.712B to $1.889B, with quarterly fluctuations but an overall positive trend. 💰 Margins & Cash Flow Gross margin stays in the high 80s to low 90s% (examples: Q4 2025 around 92%, Q2 2026 around 89%). Operating income remains solid near $2.0–$2.3B per quarter. Net cash flow from operating activities is consistently positive, typically around $2.2B–$3.2B per quarter, with occasional stronger quarter (e.g., Q4 2025, $3.16B). Investing/financing flows are mixed but liquidity strong. 🛡️ Balance Sheet & Liquidity Cash balances range roughly $5.6B–$7.0B; total assets around $28–$30B; current liabilities in the $9–12B range; long-term debt about $4–$6B; equity around $11.4–$11.8B. Leverage moderate; liquidity ample. ⚠️ Key Drivers & Risks Drivers: AI-enabled product enhancements and sustained Creative Cloud/enterprise demand. Risks: Valuation sensitivity to growth trajectory and potential macro swings in end-market demand.

ABT Analysis

ADBE Analysis

📈 Growth & Financial Trajectory

Across the observed quarters from 2024-Q2 through 2026-Q2 Abbott Laboratories shows an 8-quarter style revenue uptick, with Revenues rising from about $10.635B to $12.593B (+~~18%). Net income fluctuates, starting around $1.306B and ending near $0.928B, signaling earnings volatility despite top-line strength. Operating income remains solid (~~$1.69B in 2026-Q2) and gross margins stay in the high-50s, roughly a Gross Margin of 57–58%. Cash generation is resilient: quarterly operating cash flow from continuing activities was strong (e.g., around $2.49B in 2026-Q2), but total net cash flow swung negative in some periods due to financing activity, yielding a negative net cash flow of about $1.70B.

💰 Margins & Cash Flow

Gross Margin: high-50s to ~58%; Operating Margin around 13–14% in the latest quarter.
Operating cash flow from continuing activities generally robust; Net cash flow can be negative when financing activity dominates, as seen in 2026-Q2 (-$1.70B).

🛡️ Balance Sheet & Liquidity

Total assets approx $109B with Equity around $51.8B and Liabilities near $57.5B. Current assets vs current liabilities yields a Current ratio near 1.38, indicating solid liquidity. Leverage is moderate given the equity base and stable cash flow.

⚠️ Key Drivers & Risks

Drivers: Diversified product portfolio supporting recurring revenues; demand for diagnostics and chronic-care management.
Risks: Earnings volatility across quarters; cash flow sensitivity to financing activities and potential regulatory/currency shifts.

📈 Growth & Financial Trajectory

Over 8 quarters, revenue rose from $5.714B (Q2 2024) to $6.618B (Q2 2026), up about 16%. Net income grew from $1.712B to $1.889B, with quarterly fluctuations but an overall positive trend.

💰 Margins & Cash Flow

Gross margin stays in the high 80s to low 90s% (examples: Q4 2025 around 92%, Q2 2026 around 89%). Operating income remains solid near $2.0–$2.3B per quarter. Net cash flow from operating activities is consistently positive, typically around $2.2B–$3.2B per quarter, with occasional stronger quarter (e.g., Q4 2025, $3.16B). Investing/financing flows are mixed but liquidity strong.

🛡️ Balance Sheet & Liquidity

Cash balances range roughly $5.6B–$7.0B; total assets around $28–$30B; current liabilities in the $9–12B range; long-term debt about $4–$6B; equity around $11.4–$11.8B. Leverage moderate; liquidity ample.

⚠️ Key Drivers & Risks

Drivers: AI-enabled product enhancements and sustained Creative Cloud/enterprise demand.
Risks: Valuation sensitivity to growth trajectory and potential macro swings in end-market demand.

Similar Companies

ABBV Score: 64 BSX Score: 79 DXCM Score: 82 ELV Score: 62 ISRG Score: 84 JNJ Score: 86 MDT Score: 78 TMO Score: 75 TSLA Score: 64

Top Rated Companies

View Top 20 →

TPL "Texas Pacific Land Corp"

MPWR "MONOLITHIC POWER SYSTEMS, INC."

AMD "ADVANCED MICRO DEVICES INC"

KO "COCA COLA CO"

TEL "TE Connectivity plc"